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Abstract 
Dealing with the growing burden of age-related morbidities is one of the greatest 
challenges facing modern society. How we age across the lifecourse and how 
psychosocial and lifestyle factors interplay with the biology of ageing remains to be 
fully elucidated. Sensitive and specific biomarkers with which to interrogate the 
biology of the ageing process are sparse. Recent evidence suggests that non-coding 
RNAs are key determinants of such processes and that these can be used as 
potential circulatory bio-markers of ageing. They may also provide a mechanism 
which mediates the spread of allostatic load across the body over time, ultimately 
reflecting the immunological health and physiological status of tissues and organs. 
The interplay between exosomal microRNAs and ageing processes is still relatively 
unexplored, although circulating microRNAs have been linked to the regulation of a 
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range of physiological and pathological processes and offer insight into mechanistic 
determinants of healthspan. 
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Introduction 
Physiological, cellular and psychological changes over the life course inevitably lead 
to the impaired function of an organism [1].These changes are currently considered 
to be leading risk factors for the development of a range of morbidities. As the global 
population distribution shows a growing preponderance of elderly individuals, by 
2050 those aged over 65 years are expected to outnumber children below 15 years 
of age (http://www.who.int/world-health-day/2012/toolkit/background/en/). This shift 
will bring with it an elevated burden of age-related disease and will represent a major 
drain on health care resources worldwide.  
 
Conceptualization of the underlying mechanisms of ageing has identified nine 
hallmarks [1] comprising: genomic instability, telomere shortening, epigenetic 
alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial 
dysfunction, senescence, stem cell exhaustion and alterations in intercellular 
communication. However, not all of these hallmarks have been validated in clinical 
studies. Although research into the mechanisms of ageing processes is very 
dynamic there is still a pressing need for better understanding of ageing throughout 
the lifecourse. This is pertinent in the context of age-related morbidities and their 
relationship with psychosocial, nutritional and lifestyle factors, as well as with genetic 
and epigenetic determinants of ageing [2,3]. It still remains to be determined whether 
such factors act cumulatively, interactively or individually, in predisposition and 
progression of age related disease. We will now discuss how these factors might 
interplay and how they might regulate ageing processes across organ systems 
through the life course. 
 
 Many age-related morbidities share an underlying pathophysiological mechanism 
linked to ageing processes and thus present with a premature ageing phenotype 
[4,5]. Such phenotypes can be a direct result of disruption of cellular homeostasis, 
which can be further accelerated by both environmental factors and intrinsic 
metabolic activity leading to the generation of oxidative stress/damage, endoplasmic 
reticulum stress and mitochondrial dysfunction [3,6]. The cumulative result of this 
burden of stress and the consequent adaptation to maintain and restore 
physiological homeostasis through physiological or behavioural changes has been 
termed allostasis [7]. Constant activation, or overload of allostatic mechanisms, 
results in systemic problems. Allostasis adaptation in chronic age-associated 
diseases, for example, may result in an increase in oxidative stress, an increase in 
the activity of innate immunity and constant low-grade inflammation [2]. This is in 
keeping with the hypothesis that cellular dysregulation is a catalyst for accelerated 
ageing and can be considered a disease-causing agent [8]. 
 
 
A direct link between increasing allostatic load and all-cause mortality has been 
established in longitudinal studies [9]. Links between allostatic load and specific 
health outcomes or disease (cardiovascular disease, diabetes, osteoporosis, chronic 
kidney disease and chronic obstructive pulmonary disease), as well as a general 
decline in physical and cognitive function, have also been established [4,10–13]. 
Furthermore, the occurrence of age-related disorders has also been linked with the 
dysregulation of normal immune responses involved in the clearance of resident 
senescent cells within tissues. These cells are characterised by loss of proliferative 
function, but also by having resistance to death signals and promiscuous gene 
expression profiles [14], allowing their accumulation in aged organs/organisms. This 
situation has been observed across a broad range of degenerative disorders, as well 
as in progeroid mice and in cancer cells, suggesting that the selective removal of 
senescent cells via immune surveillance might be associated with delayed age–
related deterioration [14–16]. 
 
 
Biomarkers of ageing 
The ageing process is characterized by the presence of high inter-individual variation 
between individuals of the same chronological age; therefore there is an urgent need 
to identify informative biomarkers of ageing (BoA) to monitor the underlying 
molecular changes associated with ageing. The American Federation for Aging 
Research (AFAR) have proposed criteria for BoAs for ageing research; these state 
that a BoA must: (i) predict the rate of ageing and be a better predictor of lifespan 
than chronological age; (ii) monitor a basic process that underlies the ageing 
process, not the effects of disease; (iii) be able to be tested repeatedly without 
harming the individual; and (iv) be  measurable in humans and in laboratory animals 
[17]. 
 
A sequitur for any valid BoA, under these criteria, would be that it shows a 
statistically significant association with a measure of health or organ functional 
capacity and chronological age. Furthermore, such a relationship must be 
statistically significant for all three pairwise associations. This is critical when 
applying BoA in the context of morbidities; features related to a specific morbidity 
must be delineated from those of the ageing process per se. Consequently, there is 
a paucity of biomarkers fulfilling these criteria in any robust fashion.  
 
Recent approaches to identify more robust biomarkers have focussed on using renal 
allografts as a source of healthy tissue whose function can be followed longitudinally 
and in which context BoA can be compared ‘head to head’. This approach initially 
identified CDKN2A expression as a robust biomarker, outperforming telomere length 
(a more traditional biomarker of ageing) in explaining inter-individual variation in 
renal function with age. Notably, many putative BoA identified in studies in model 
organisms failed to meet the AFAR criteria in the human specific renal system, 
indicating that they were more intimately linked to disease processes rather than 
ageing [18–21]. 
 
More recently, epigenetic analyses of the ageing process has led to the identification 
of a small number of micro RNAs (miRNAs), regulating the CDKN2 locus and 
associated with biochemical pathways implicated in regulating organismal longevity 
[22]. Critically, these miRNAs regulate common cellular metabolic pathways linked to 
nutritional stress, DNA repair processes, autophagy and protein synthesis. 
Moreover, these biochemical functions are common across taxa, indicating the 
substantive biological commonality in fundamental ageing processes. These 
observations are in keeping with the original mitochondrion/telomere nucleoprotein 
complex/ribosome (MTR) postulate of Shiels and Davies (2003), whereby cellular 
ageing processes are linked tightly to macromolecular damage responses, energy 
availability and utilization [23,24]. The question remains, however, as to how one can 
extrapolate markers of cellular ageing to the ageing of the whole organism and 
whether these markers remain reflective of allostatic load, or reflect ongoing aspects 
of more local disease processes? This is particularly pertinent in the context of 
segmental ageing, where individual genes, such as those that give rise to unimodal 
progerias (e.g. WRN, Lamin A, BLM [25,26])  or genetic pathways that extend 
lifespan (e.g. mechanistic target of rapamycin [mTOR]) are likely to have non-
uniform and non-cell-autonomous effects on the decline in tissue and organ function 
with increasing age.  By extension, this implies that there is a direct interconnection 
between separate systems for tissue/organ and organismal ageing. In this context, 
regulation of circadian rhythms at a cellular, tissue and organismal level may provide 
an appropriate paradigm [2,3]. Of note, under the aegis of such a hypothesis, 
interventions to combat age-related decline in organ and tissue function might have 
unintended adverse consequences. By way of illustration, the use of caloric 
restriction to improve healthspan, for example, has resulted in a reduction in bone 
mineral density [27]. 
 
 
Exosomes, ageing and allostatic load 
How ageing in one organ spreads its effects across the whole body and contributes 
to organismal allostatic load is an area of intense investigation. The BoA signature of 
age-related healthy renal function points towards epigenetic regulation as being a 
key feature of such a process. This is pertinent to the capacity of extracellular 
secretory vesicles (ESVs) to impact on non-cell autonomous ageing processes, 
which may be coupled with autophagy. A key class of such ESVs subject to much 
investigation are exosomes. 
 
Exosomes are small, extracellular secretory vesicles (30-100 nm) containing a 
membranous lipid bilayer and originating from intercellular endosomal 
compartments, the contents of which vary significantly between cell types [28–30]. 
These have been demonstrated to facilitate intercellular communication, including 
stimulation of immune responses to promote wound healing [31] and may have a 
role in maintaining tissue homeostasis. Exosomes have also been postulated as a 
therapeutic vehicle to treat diseases of ageing, such as diabetes [32,33], 
cardiovascular disease [34], Alzheimer’s disease [35] and chronic kidney disease 
[36–38]. 
Interestingly, altered miRNA profiles and lysosomal profiles have also been found in 
exosomes collected from subjects diagnosed with diseases of ageing, such as 
Parkinson’s and Alzheimer’s diseases [39,40]. The presence of misfolded proteins in 
exosomes, particularly prion-like proteins, has also been demonstrated in other 
neurodegenerative diseases including Creutzfeldt-Jakob disease [41].  
There is a growing body of evidence demonstrating modulation of exosomal, 
contents by stress induction [42], which may impact the lifecourse, and therefore will 
be associated with allostatic load and driven by ageing. These modulators include 
both biophysical and metabolic stressors, such as nutrient deprivation [43], heat [44], 
hypoxia, or irradiation [45]. Critically, following on from a thesis that stress 
accelerates ageing and that early onset of diseases of ageing result from this, 
exosomal contents are modified by several of the “stress” hormones. For example, 
corticosteroid can induce myocilin (MYOC), which is linked to glaucoma [46]. 
Glucocorticoid stimulation can also increase the levels of specific miRNAs namely 
miR-23a [47] and miR-182 [48] within exosomes without influencing the secretion 
levels of exosomes overall. These miRNAs have also been linked to regulation of 
FOXP3 and calcineurin signalling in muscle atrophy and muscle wasting. 
These observations are pertinent to psychosocial and lifestyle factors, which are 
both associated with the accrual of allostatic load and the acceleration of ageing 
[4,49–51] and may link accelerated ageing with poor nutrition and inflammation, both 
at a cellular level and at a general population level. 
 
This association with inflammation and nutrition has been further strengthened by 
the observations that hyperphosphatemia, a proven cause of accelerated ageing in 
mammals [52–55], is nutritionally driven. Furthermore, it is linked to accelerated 
ageing and early onset disease in man and associated with the frequency of red 
meat consumption in a setting of social deprivation [56]. The importance of 
phosphate in the accelerated ageing phenotype can be linked to vascular 
calcification and formation of cytotoxic calciprotein particles (CPPs), a common 
feature of many metabolic and accelerated ageing syndromes. Since phosphate 
activates the ACT/mTORC1 blockade of mTORC1 may have therapeutic potential 
for premature aging-like symptoms [57].Vascular calcification, a common feature in 
the ageing process, can be counteracted by Fetuin A, a putative marker of ageing, 
characterised by reduced concentration in a number of pathologies associated with 
accelerated ageing including chronic kidney disease and cancer [58–60]. Recent in 
vivo and in vitro results also suggest that lamin A plays an important role in the 
process of premature vascular ageing [61]. Recent studies investigating the role of 
senescent associated phenotype (SASP) in smooth vascular cell ageing has 
revealed that changes in expression and contents of exosomes are associated with 
vascular calcification [62]. Exosomes generated from senescent vascular smooth 
muscle cells are altered in terms of the proteins, miRNAs and minerals they contain 
[62]. These exosomes directly drive the disease pathology, demonstrated by 
blocking of exosome secretion and subsequent amelioration of pathology [63]. 
 
The link between ageing, inflammation and nutrition is also pertinent to non-coding 
RNA regulation of healthy ageing processes [64]. Recently, changes in both 
circulating and membrane marker levels, used to classify a broad range of 
extracellular vesicles (EVs) including exosomes, have been observed in association 
with age-related structural and functional changes in solid organs, [65]. In this 
context, the exosomal secretome from senescent cells has been hypothesized as a 
potential contributor to age-associated inflammation and decline in immune function 
[66–72]. This, when coupled with DNA damage response (DDR) signaling, has been 
implicated in the generation of pro-inflammatory senescence-associated secretory 
phenotype (SASP). The relative contribution of the SASP to age-related 
inflammatory status, while intuitive, has proved to be modest in general population 
cohort studies, where BoAs, such as telomere length in circulating leukocytes, have 
explained less than 10% of inter-individual variation in inflammatory status [51,73–
75].  
 
The contribution of exosomal non-coding RNAs in this context remains to be proven, 
but might well help to explain a greater proportion of this inter-individual variation in 
the inflammatory status or a correlative predisposition to age-related diseases [72]. 
Additionally, it may help to explain how exosomes are able to generate a pro-tumor 
environment that is essential for carcinogenesis through maintenance of an 
oncogenic niche and modulation of immune function [76]. 
 
 
Conclusions 
 
Modulation of the ageing process over the lifecourse is complex, comprising 
advertent regulation of a range of biochemical processes via psychosocial, lifestyle 
and nutritional factors in association with genetic and epigenetic determinants of 
ageing. The cumulative result of their actions is morbidity and eventual mortality. A 
range of biomarker studies, as we have described, indicates that the accumulation of 
senescent cells results in decreased tissue and organ function, increased allostatic 
load and accompanying inflammatory burden. The epigenetic component, which has 
the capacity to transmit both intergenerationally and transgenerationally, is 
particularly intriguing, as it may act as the body’s hamartia in facilitating the spread of 
allostatic load across the whole organism. Consequently, this process may, through 
the transmission of exosome non-coding RNAs, help regulate niches for the 
progression and spread of disease as well as providing system-wide cues for 
allostatic responses. The expression, composition and function of exosomes are 
modulated by a range of stress hormones enabling a dynamic response to 
environmental triggers at a cellular level. As such, their modulation may serve as an 
excellent target for future therapeutic interventions in  reducing age-related 
morbidities and improving health span. It is also likely that better understanding of 
the biology of exceptionally long-lived animals, such as naked mole rats, which 
possess a 30 year lifespan, will contribute to better understanding of ageing 
processes [5].  
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